These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 23131559)

  • 1. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
    Fujisaki S; Imai M; Takashita E; Taniwaki T; Xu H; Kishida N; Yokoyama M; Sato H; Tashiro M; Odagiri T
    J Infect Chemother; 2013 Oct; 19(5):891-5. PubMed ID: 23529501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
    Tamura D; Nguyen HT; Sleeman K; Levine M; Mishin VP; Yang H; Guo Z; Okomo-Adhiambo M; Xu X; Stevens J; Gubareva LV
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6141-6. PubMed ID: 24080660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Farrukee R; Butler J; Reading PC; Hurt AC
    Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
    Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y
    Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
    McKimm-Breschkin JL; Barrett S
    Antiviral Res; 2015 Feb; 114():62-6. PubMed ID: 25499124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
    Mohr PG; Williams J; Tashiro M; Streltsov VA; McKimm-Breschkin JL
    Antiviral Res; 2020 Oct; 182():104895. PubMed ID: 32750469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
    Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
    Stoner TD; Krauss S; DuBois RM; Negovetich NJ; Stallknecht DE; Senne DA; Gramer MR; Swafford S; DeLiberto T; Govorkova EA; Webster RG
    J Virol; 2010 Oct; 84(19):9800-9. PubMed ID: 20660186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
    Tran-To Su C; Ouyang X; Zheng J; Kwoh CK
    BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
    Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
    Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
    Yen HL; McKimm-Breschkin JL; Choy KT; Wong DD; Cheung PP; Zhou J; Ng IH; Zhu H; Webby RJ; Guan Y; Webster RG; Peiris JS
    mBio; 2013 Jul; 4(4):. PubMed ID: 23860768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
    Pan P; Li L; Li Y; Li D; Hou T
    Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].
    Reina J
    Rev Esp Quimioter; 2006 Dec; 19(4):317-22. PubMed ID: 17235399
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
    Baz M; Abed Y; Boivin G
    Antiviral Res; 2007 May; 74(2):159-62. PubMed ID: 17137644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
    Takashita E; Meijer A; Lackenby A; Gubareva L; Rebelo-de-Andrade H; Besselaar T; Fry A; Gregory V; Leang SK; Huang W; Lo J; Pereyaslov D; Siqueira MM; Wang D; Mak GC; Zhang W; Daniels RS; Hurt AC; Tashiro M
    Antiviral Res; 2015 May; 117():27-38. PubMed ID: 25721488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.